Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) shares fell 5.7% during mid-day trading on Tuesday . The stock traded as low as $13.60 and last traded at $13.60. 495 shares changed hands during trading, a decline of 93% from the average session volume of 6,787 shares. The stock had previously closed at $14.42.
Analyst Ratings Changes
Separately, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Adlai Nortye in a report on Friday, January 12th.
Read Our Latest Research Report on ANL
Adlai Nortye Stock Down 13.6 %
The company has a 50 day simple moving average of $8.95 and a 200-day simple moving average of $9.23.
Institutional Investors Weigh In On Adlai Nortye
A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. grew its stake in shares of Adlai Nortye Ltd. (NASDAQ:ANL - Free Report) by 128.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 40,310 shares of the company's stock after purchasing an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned approximately 0.11% of Adlai Nortye worth $362,000 as of its most recent filing with the Securities and Exchange Commission. 35.21% of the stock is currently owned by hedge funds and other institutional investors.
Adlai Nortye Company Profile
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Further Reading
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
